Clinical Overview of Leber Hereditary Optic Neuropathy
Open Access
- 29 June 2022
- journal article
- research article
- Published by Vilnius University Press in Acta medica Lituanica
- Vol. 29 (1) , 9-18
Abstract
Leber hereditary ptic neuropathy (LHON) is a disease of young adults with bilateral, painless, subacute visual loss. The peak age of onset of LHON is in the second and third decades of life. Men are 4 times more likely to be affected than women. In about 25-50% of cases, both eyes are affected simultaneously. In unilateral cases, the other eye is usually affected 2 to 3 months later. Visual acuity deteriorates to counting fingers or worse with a dense central or centrocecal scotoma. In the subacute phase, the optic disc may appear hyperemic with swelling of the peripapillary retinal nerve fibre layer, peripapillary telangiectasias, and increased vascular tortuosity. Ocular coherence tomography of the macula shows marked thinning of the ganglion cell complex even at this stage. The diagnosis of LHON is made in a subject with a consistent clinical history and/or one of three common pathogenic mitochondrial DNA (mtDNA) variants identified by molecular genetic testing. Idebenone was approved by the European Medicines Agency under exceptional circumstances for the treatment of LHON. Current evidence suggests some benefit to vision in a subset of affected individuals treated with idebenone, particularly when treated within the first year of onset of vision loss. In this article, we discuss aetiology, clinical features, diagnosis, differential dignosis, prognosis and treatment.Keywords
This publication has 71 references indexed in Scilit:
- Effects of Idebenone on Color Vision in Patients With Leber Hereditary Optic NeuropathyJournal of Neuro-Ophthalmology, 2013
- Leber hereditary optic neuropathy and oxidative stressProceedings of the National Academy of Sciences, 2012
- Idebenone Protects against Retinal Damage and Loss of Vision in a Mouse Model of Leber’s Hereditary Optic NeuropathyPLOS ONE, 2012
- Treatment of hereditary optic neuropathiesNature Reviews Neurology, 2012
- A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathyBrain, 2011
- NQO1-Dependent Redox Cycling of Idebenone: Effects on Cellular Redox Potential and Energy LevelsPLOS ONE, 2011
- Mitochondrial optic neuropathies – Disease mechanisms and therapeutic strategiesProgress in Retinal and Eye Research, 2011
- Gene–environment interactions in Leber hereditary optic neuropathyBrain, 2009
- Inherited mitochondrial optic neuropathiesJournal of Medical Genetics, 2008
- Inhibition of lipid peroxidation by idebenone in brain mitochondria in the presence of succinateArchives of Gerontology and Geriatrics, 1989